Restrictive Red Blood Cell Transfusion Is Safe for Most Patients — Except in Neurocritical Care (and Some Bleeding Syndromes)
Posted inAnesthesiology Critical Care Hematology-Oncology news

Restrictive Red Blood Cell Transfusion Is Safe for Most Patients — Except in Neurocritical Care (and Some Bleeding Syndromes)

A Cochrane update (2025) of 69 randomized trials found restrictive RBC transfusion thresholds (typically Hb 7–8 g/dL) cut transfusion exposure ~42% without increasing 30‑day mortality overall, but liberal strategies improved long‑term neurological outcomes after brain injury and restrictive thresholds reduced mortality in GI bleeding.
Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results
Posted inHematology-Oncology news

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in relapsed/refractory multiple myeloma.
Selective JAK2 Inhibition OB756 Shows Promise in Hydroxyurea/Interferon‑Intolerant or -Resistant Essential Thrombocythemia
Posted inHematology-Oncology news

Selective JAK2 Inhibition OB756 Shows Promise in Hydroxyurea/Interferon‑Intolerant or -Resistant Essential Thrombocythemia

A Phase II multicenter study reports that OB756, a selective JAK2 inhibitor, is active and reasonably well tolerated in hydroxyurea- or interferon-intolerant/resistant essential thrombocythemia, producing platelet and leukocyte control, spleen volume reduction, symptom improvement and reductions in JAK2 V617F allele burden.
Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen
Posted inHematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.